To predict the therapeutical effect and adverse reaction of methotrexate based on Metabonomics

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800015307

Enrollment

Unknown

Registered

2018-03-21

Start date

2016-01-01

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Age

1 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Recommendations for the diagnosis and treatment of childhood acute lymphoblastic leukemia published in the Blood Group of the Chinese Academy of Pediatric Pediatrics Section 2014 and Chinese adults released in 2016 according to the Chinese Society of Anticancer Association Hematological Oncology and the Leukemia Lymphoma Group of the Chinese Medical Association Hematology Branch. The diagnosis and treatment guidelines for acute lymphoblastic leukemia were diagnosed as acute lymphoblastic leukemia patients; 2) Aged 1-40 years old; 3) The Han nationality; 4) receiving high-dose methotrexate administration and blood concentration testing; 5) Sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Other ethnic minority patients; 2) Combining other types of blood diseases; 3) Patients with severe liver and kidney function diseases and gastrointestinal disorders, mucositis and other diseases; 4) Patients with allergies or allergies to methotrexate

Design outcomes

Primary

Measure	Time frame
genotype;	—

Countries

China

Contacts

Public ContactXia He

Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital

yaan_hbx@163.com+86 15982274601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026